At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
SI-722 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of SI-722 Intravesical Instillation in Interstitial Cystitis/Bladder Pain Syndrome Subjects
In Brief
A Phase 2 clinical trial evaluating SI-722 and Placebo for Interstitial Cystitis and Bladder Pain Syndrome. Completed, enrolled 33 participants across 5 sites.
Detailed Summary
This study is designed randomized, double-blind, placebo-controlled trial in Interstitial Cystitis/Bladder Pain Syndrome patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInterstitial Cystitis, Bladder Pain Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartMar 2020
Primary CompletionJan 2021
TodayJul 2026
First PostedDec 23, 2019
Enrollment StartMar 30, 2020
Primary CompletionJan 12, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.5 years ago
Interventions
SI-722drug
SI-722 will be intravesically instilled.
Placebodrug
Placebo will be intravesically instilled.